- Details
- Zachary Klaassen interviews James Wasielewski, the first patient to receive Pluvicto™ following its FDA approval for pre-chemotherapy metastatic castration-resistant prostate cancer. Mr. Wasielewski describes how his rising PSA after years on leuprolide and enzalutamide prompted discussions about next treatment options with Dr. Finkelstein, ultimately leading to his decision to pursue this targete...
|
- Details
- Zachary Klaassen speaks with Steven Finkelstein about the FDA approval of Pluvicto™ (177Lu-PSMA-617) in the pre-chemotherapy setting for metastatic castration-resistant prostate cancer. Dr. Finkelstein discusses his team's achievement of treating the first U.S. patient under this new indication just six days after the March 28, 2025 approval. He highlights results from the PSMAfore trial showing P...
|
- Details
- Zachary Klaassen interviews Alessio Crippa about the prognostic value of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer from the ProBio trial. Dr. Crippa explains how this adaptive platform trial uses non-invasive liquid biopsies to characterize patients' tumor genetic profiles, guiding treatment randomization. Their recent European Urology Oncology publication de...
|
- Details
- Zachary Klaassen speaks with Oliver Sartor about the FDA's expanded approval of Pluvicto™ (177Lu-PSMA-617) for metastatic castration-resistant prostate cancer patients in the taxane-naive setting. Dr. Sartor discusses the PSMAfore trial that led to this expansion, which showed a 59% reduction in progression risk compared to alternative ARPI therapy. This approval dramatically changes treatment seq...
|
- Details
- Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the Spanish cohort of the ARAMIS trial after progression to metastatic castration-resistant prostate cancer (mCRPC). From the 85 evaluable patients, he highlights several key findings: 29% received no fu...
|
- Details
- Oliver Sartor speaks with Alicia Morgans about a long-term study investigating cognitive effects in men with metastatic castration-resistant prostate cancer treated with abiraterone versus enzalutamide. Dr. Morgans discusses how the study evolved from observations made around 2014-2015 regarding potential cognitive impacts of ADT. She outlines the non-randomized trial design which followed patient...
|
- Details
- Alicia Morgans hosts Rana McKay to discuss the PREDICT trial, a biomarker-driven study addressing the unmet need for personalized therapy in advanced prostate cancer. Dr. McKay explains that the trial emerged from a working group seeking to overcome limitations of the NCI-MATCH study for bone-predominant prostate cancer patients. PREDICT enrolls mCRPC patients previously treated with an ARPI and a...
|
- Details
- Neeraj Agarwal discusses with Yeonjung Jo and Umang Swami research comparing time from medication order to administration of cabazitaxel versus lutetium-177 in mCRPC patients. Using the Flatiron Health database of 2,329 medication orders, they found significantly longer delays for lutetium (median 22 days) compared to cabazitaxel (median 7 days). This disparity exists across both academic and comm...
|
- Details
- Fred Saad joins Zachary Klaassen to discuss a subgroup analysis of the PEACE-3 trial, which evaluated enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. Dr. Saad highlights how bone-protective agents (BPAs), made mandatory after high fracture rates were observed, significantly impact outcomes. Among 115 pre-mandate patients, those receiving BPAs gained 14 m...
|
- Details
- Alicia Morgans is joined by Alan Bryce to discuss the TRITON3 trial's final overall survival data. This phase III study evaluated rucaparib against physician's choice therapy (predominantly docetaxel) in pre-chemotherapy mCRPC patients with BRCA1/2 or ATM mutations. While rucaparib previously demonstrated superior radiographic progression-free survival, including being the first therapy to outperf...
|
